<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820985</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2020-01/SH-01</org_study_id>
    <nct_id>NCT04820985</nct_id>
  </id_info>
  <brief_title>Analysis of the Composition of the Vaginal Microbiota During IVF Treatment and Correlation With Serum Progesterone Level on the Day of Embryo Transfer</brief_title>
  <acronym>MICROFIV</acronym>
  <official_title>Analyse de la Composition du Microbiote Vaginal à différents Temps de la Prise en Charge en FIV et corrélation Avec le Taux de progestérone sérique le Jour du Transfert d'Embryon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The composition of the vaginal microbiota varies throughout a woman's life and is sensitive&#xD;
      to hormonal and environmental factors. Specifically, hormonal treatments necessary in the&#xD;
      medically assisted procreation (MAP) processes can influence the vaginal microbiota. New&#xD;
      sequencing techniques have been used to characterize the vaginal microbiota, demonstrating&#xD;
      that the microbiota could be divided into 5 classes. The composition of the vaginal&#xD;
      microbiota seems to have an implication in the evolution of a pregnancy after IVF. It is&#xD;
      therefore essential to have more data on the evolution of the vaginal microbiota at the&#xD;
      different stages of IVF treatment and to analyze whether this evolution can be predictive of&#xD;
      the success of embryo implantation. Good endometrial progesterone impregnation is an&#xD;
      essential prerequisite for ensuring embryo implantation. Indeed, supporting the luteal phase&#xD;
      through vaginal progesterone is an essential step in IVF protocols to ensure synchronization&#xD;
      between endometrial maturation and embryonic age. However, the serum progesterone level on&#xD;
      the day of embryo transfer varies widely between patients. Several factors such as age,&#xD;
      vaginal mucosa trophicity, estrogen impregnation and sexual activity are known to affect the&#xD;
      vaginal absorption of progesterone. The treatments and vaginal examinations performed during&#xD;
      the IVF procedure could also have an impact on the constitution of the vaginal microbiota.&#xD;
      The hypothesis of this research is that there is an alteration in the vaginal microbiota&#xD;
      during the IVF process which may alter the absorption of vaginal progesterone, with an impact&#xD;
      on the failure or success of embryo implantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Class of vaginal flora according to community state type</measure>
    <time_frame>3 Months before ovarian stimulation</time_frame>
    <description>Classified into 5 classes of vaginal flora described according to Smith &amp; Ravel 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiota richness of vaginal flora</measure>
    <time_frame>3 Months before ovarian stimulation</time_frame>
    <description>Measured by operational taxonomic unit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiota alpha diversity of vaginal flora</measure>
    <time_frame>3 Months before ovarian stimulation</time_frame>
    <description>Shannon Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiota beta diversity of vaginal flora</measure>
    <time_frame>3 Months before ovarian stimulation</time_frame>
    <description>Bray Curtis index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma progesterone level on the day of embryo transfer</measure>
    <time_frame>Day of embryo transfer (Day 0)</time_frame>
    <description>Measured by chemiluminescence (nmol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Class of vaginal flora according to community state type</measure>
    <time_frame>Day of oocyte puncture (Month 3)</time_frame>
    <description>Classified into 5 classes of vaginal flora described according to Smith &amp; Ravel 2017</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Class of vaginal flora according to community state type</measure>
    <time_frame>Day of embryo transfer (Day 93)</time_frame>
    <description>Classified into 5 classes of vaginal flora described according to Smith &amp; Ravel 2017</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Class of vaginal flora according to community state type</measure>
    <time_frame>Day of beta-human chorionic gonadotropin dosage (Day 108)</time_frame>
    <description>Classified into 5 classes of vaginal flora described according to Smith &amp; Ravel 2017</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota richness of vaginal flora</measure>
    <time_frame>Day of oocyte puncture (Month 3)</time_frame>
    <description>Measured by operational taxonomic unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota richness of vaginal flora</measure>
    <time_frame>Day of embryo transfer (Day 93)</time_frame>
    <description>Measured by operational taxonomic unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota richness of vaginal flora</measure>
    <time_frame>Day of beta-human chorionic gonadotropin dosage (Day 108)</time_frame>
    <description>Measured by operational taxonomic unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota alpha diversity of vaginal flora</measure>
    <time_frame>Day of oocyte puncture (Month 3)</time_frame>
    <description>Shannon Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota alpha diversity of vaginal flora</measure>
    <time_frame>Day of embryo transfer (Day 93)</time_frame>
    <description>Shannon Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota alpha diversity of vaginal flora</measure>
    <time_frame>Day of beta-human chorionic gonadotropin dosage (Day 108)</time_frame>
    <description>Shannon Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota beta diversity of vaginal flora</measure>
    <time_frame>Day of oocyte puncture (Month 3)</time_frame>
    <description>Bray Curtis index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota beta diversity of vaginal flora</measure>
    <time_frame>Day of embryo transfer (Day 93)</time_frame>
    <description>Bray Curtis index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota beta diversity of vaginal flora</measure>
    <time_frame>Day of beta-human chorionic gonadotropin dosage (Day 108)</time_frame>
    <description>Bray Curtis index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy success</measure>
    <time_frame>Month 3</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy progression</measure>
    <time_frame>Month 3</time_frame>
    <description>Implantation failure/progression/miscarriage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatments received for IVF</measure>
    <time_frame>Month 3</time_frame>
    <description>Description of treatments, taken from patient file</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma progesterone level</measure>
    <time_frame>Month 3</time_frame>
    <description>Measured by chemiluminescence (nmol/L)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>Women undergoing IVF</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vaginal swab</intervention_name>
    <description>Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing</description>
    <arm_group_label>Women undergoing IVF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood sample to measure plasma dose of progesterone</description>
    <arm_group_label>Women undergoing IVF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18 to 40 inclusive, Round1 or 2 of IVF or IVF-ICSI with fresh embryo&#xD;
        transfer, without taking antibiotics in the 3 months preceding the first sample treated in&#xD;
        the AMP center of the CHU de Nîmes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient in round 1 or 2 of IVF or IVF-ICSI with transfer of a fresh embryo with a&#xD;
             normal preimplantation assessment, without antibiotic treatment in the 3 months&#xD;
             preceding the sample.&#xD;
&#xD;
          -  The patient must have given their free and informed consent and signed the consent&#xD;
             form&#xD;
&#xD;
          -  The patient must be a member or beneficiary of a health insurance plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of antibiotics in the 3 months preceding the sample.&#xD;
&#xD;
          -  Patient presenting an anomaly in the implantation assessment.&#xD;
&#xD;
          -  Presence of uterine malformation, hydrosalpinx, chronic vaginosis.&#xD;
&#xD;
          -  Patient undergoing a protocol to study endometrial receptivity.&#xD;
&#xD;
          -  Patient of African American, African or Latin American origin (patients born to two&#xD;
             parents of Hispanic origin) as people of African and Hispanic origin have a type IV&#xD;
             flora vs people of Caucasian origins who have type I, II, III and V of the Ravel&#xD;
             classification .&#xD;
&#xD;
          -  Cancellation of the procedure for various reasons (stimulation failure, collection&#xD;
             failure, fertilization failure or embryonic segmentation).&#xD;
&#xD;
          -  Patient taking a freeze-all approach (freezing of the embryos) for various causes&#xD;
             (risk of ovarian hyperstimulation, increase in progesterone, too thin endometrium,&#xD;
             etc.).&#xD;
&#xD;
          -  The subject is participating in a category 1 interventional study, or is in a period&#xD;
             of exclusion determined by a previous study&#xD;
&#xD;
          -  The subject refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to give the subject informed information&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Stéphanie Huberlant</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphanie Huberlant</last_name>
    <phone>.66.68.32.20</phone>
    <email>stephanie.huberlant@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie Huberlant</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Rougier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Letouzey</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe Lavigne</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Dunyach-Remy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Smith SB, Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol. 2017 Jan 15;595(2):451-463. doi: 10.1113/JP271694. Epub 2016 May 5. Review.</citation>
    <PMID>27373840</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>vaginal microbiota</keyword>
  <keyword>Progesterone</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

